[1]. P. Corcia H. F. Jafari-Schluep D. Lardillie et al.2003 A clustering of conjugal amyotrophic lateral sclerosis in southeastern France Arch. Neurol. 60 553–557.

[1]. P. Corcia H. F. Jafari-Schluep D. Lardillie 2003 A clustering of conjugal amyotrophic lateral sclerosis in southeastern France Arch. Neurol. 60 553–557.)| false
• Search Google Scholar
• Export Citation

[2]. A. C. Ludolph J. Hugon M. P. Dwivedi et al.1987 Studies on the aetiology and pathogenesis of motor neuron diseases. Lathyrism: clinical findings in established cases Brain 110 149–165.

[2]. A. C. Ludolph J. Hugon M. P. Dwivedi 1987 Studies on the aetiology and pathogenesis of motor neuron diseases. Lathyrism: clinical findings in established cases Brain 110 149–165.)| false
• Search Google Scholar
• Export Citation

[3]. R. C. Brown A. H. Lockwood B. R. Sonawane 2005 Neurodegenerative diseases: an overview of environmental risk factors Environ. Health Perspect. 113 1250–1256.

[3]. R. C. Brown A. H. Lockwood B. R. Sonawane 2005 Neurodegenerative diseases: an overview of environmental risk factors Environ. Health Perspect. 113 1250–1256.)| false
• Search Google Scholar
• Export Citation

[4]. P. R. Heath P. J. Shaw 2002 Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis Muscle Nerve 26 438–458.

[4]. P. R. Heath P. J. Shaw 2002 Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis Muscle Nerve 26 438–458.)| false
• Search Google Scholar
• Export Citation

[5]. U. K. Misra J. Kalita V. N. Mishra et al.2005 A clinical, magnetic resonance imaging and survival motor neuron gene deletion study of Hirayama disease Arch. Neurol. 62 120–123.

[5]. U. K. Misra J. Kalita V. N. Mishra 2005 A clinical, magnetic resonance imaging and survival motor neuron gene deletion study of Hirayama disease Arch. Neurol. 62 120–123.)| false
• Search Google Scholar
• Export Citation

[6]. S. Ito S. Kuwabara T. Fukutake et al.2005 HyperIgEaemia in patients with juvenile muscular atrophy of the distal upper extremity (Hirayama disease) J. Neurol. Neurosurg. Psychiatr. 76 132–134.

[6]. S. Ito S. Kuwabara T. Fukutake 2005 HyperIgEaemia in patients with juvenile muscular atrophy of the distal upper extremity (Hirayama disease) J. Neurol. Neurosurg. Psychiatr. 76 132–134.)| false
• Search Google Scholar
• Export Citation

[7]. B. W. Ennis L. M. Matrisian 1994 Matrix degrading metalloproteinases J. Neuro. Oncol. 18 105–109.

[7]. B. W. Ennis L. M. Matrisian 1994 Matrix degrading metalloproteinases J. Neuro. Oncol. 18 105–109.)| false
• Search Google Scholar
• Export Citation

[8]. G. P. Lim J. R. Backstrom M. J. Cullen et al.1996 Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients J. Neurochem. 67 251–259.

[8]. G. P. Lim J. R. Backstrom M. J. Cullen 1996 Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients J. Neurochem. 67 251–259.)| false
• Search Google Scholar
• Export Citation

[9]. W. M. Beuche M. Yushchenko M. Mader et al.2000 Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis NeuroReport 11 3419–3422.

[9]. W. M. Beuche M. Yushchenko M. Mader 2000 Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis NeuroReport 11 3419–3422.)| false
• Search Google Scholar
• Export Citation

[10]. S. Lorenzl S. Narr B. Angele et al.2006 The matrix metalloproteinases inhibitor Ro 26-2853 extends survival in transgenic ALS mice Exp. Neurol. 200 166–171.

[10]. S. Lorenzl S. Narr B. Angele 2006 The matrix metalloproteinases inhibitor Ro 26-2853 extends survival in transgenic ALS mice Exp. Neurol. 200 166–171.)| false
• Search Google Scholar
• Export Citation

[11]. S. Lorenzl G. De Pasquale A. Z. Segal et al.2003 Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia Stroke 34 37–38.

[11]. S. Lorenzl G. De Pasquale A. Z. Segal 2003 Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia Stroke 34 37–38.)| false
• Search Google Scholar
• Export Citation

[12]. B.G. Schoser D. Blottner 1999 Matrix metalloproteinases MMP-2, MMP-7 and MMP-9 in denervated human muscle NeuroReport. 10 2795–2797.

[12]. B.G. Schoser D. Blottner 1999 Matrix metalloproteinases MMP-2, MMP-7 and MMP-9 in denervated human muscle NeuroReport. 10 2795–2797.)| false
• Search Google Scholar
• Export Citation

[13]. M. Demestre M. Orth G. M. Wells et al.2005 Characterization of matrix metalloproteinases in denervated muscle Neuropathol. Appl. Neurobiol. 31 545–555.

[13]. M. Demestre M. Orth G. M. Wells 2005 Characterization of matrix metalloproteinases in denervated muscle Neuropathol. Appl. Neurobiol. 31 545–555.)| false
• Search Google Scholar
• Export Citation

[14]. B. R. Brooks 1994 El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors J. Neurol. Sci. 124 96–107.

[14]. B. R. Brooks 1994 El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors J. Neurol. Sci. 124 96–107.)| false
• Search Google Scholar
• Export Citation

[15]. F. H. Norris Jr. P. R. Calanchini R. J. Fallat et al.1974 The administration of guanidine in amyotrophic lateral sclerosis Neurology 24 721–728.

[15]. F. H. Norris Jr. P. R. Calanchini R. J. Fallat 1974 The administration of guanidine in amyotrophic lateral sclerosis Neurology 24 721–728.)| false
• Search Google Scholar
• Export Citation

[16]. K. Mahmoud K. Khatuna Y. C. Noel et al.2007 Matrix metalloproteinase-9 regulates TNF-α and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis Exp. Neurol. 205 74–81.

[16]. K. Mahmoud K. Khatuna Y. C. Noel 2007 Matrix metalloproteinase-9 regulates TNF-α and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis Exp. Neurol. 205 74–81.)| false
• Search Google Scholar
• Export Citation

[17]. M. Kiaei S. Petri K. Kipiani et al.2006 Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis J. Neurosci. 26 2467–2473.

[17]. M. Kiaei S. Petri K. Kipiani 2006 Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis J. Neurosci. 26 2467–2473.)| false
• Search Google Scholar
• Export Citation